Pharmacological interventions, including renin–angiotensin system antagonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors and novel mineralocorticoid receptor blockers are valuable in managing these complex conditions, although frequently difficult or impossible to use in advanced kidney disease. This evidence concerns the gene SLC5A2 and kidney disorder.